Abstract: Human respiratory syncytial virus (HRSV) causes serious pediatric infection of the lower respiratory tract without effective therapeutic modality. Sheng-Ma-Ge-Gen-Tang (SMGGT; Shoma-kakkon-to) has been proven to be effective at inhibiting HRSV-induced plaque formation, and Cimicifuga foetida is the major constituent of SMGGT. We tested the hypothesis that C. foetida effectively inhibited the cytopathic effects of HRSV by a plaque reduction assay in both human upper (HEp2) and lower (A549) respiratory tract cell lines. Its ability to stimulate anti-viral cytokines was evaluated by an enzyme-linked immunosorbent assay (ELISA). C. foetida dose-dependently inhibited HRSV-induced plaque formation ð p < 0:0001Þ before and after viral inoculation, especially in A549 cells ð p < 0:0001Þ. C. foetida dose-dependently inhibited viral attachment ð p < 0:0001Þ and could increase heparins effect on viral attachment. In addition, C. foetida time-dependently and dosedependently ð p < 0:0001Þ inhibited HRSV internalization. C. foetida could stimulate epithelial cells to secrete IFN-β to counteract viral infection. However, C. foetida did not stimulate TNF-secretion. Therefore, C. foetida could be useful in managing HRSV infection. This is the first evidence to support that C. foetida possesses antiviral activity.
Introduction
Human respiratory syncytial virus (HRSV) is a major cause of lower respiratory tract infections in infants, young children, and adults (Falsey and Walsh, 2000) . HRSV is the most major viral pathogen of the respiratory tract in infants younger than one year old (Collins and Crowe, 2007; Collins and Graham, 2008) . Infection and re-infection with HRSV are most frequent during the first few years of life (Collins and Crowe, 2007) . Therefore, of all children that are infected by 24 months, half experienced two infections (Collins and Crowe, 2007) . Effective therapeutic modalities are highly needed. However, only supportive care is given to manage HRSV-induced severe lower respiratory tract infection (Collins and Crowe, 2007) . Ribavirin is a guanosine analogue that is an inhibitor of inosine monophosphate (IMP) dehydrogenase. It interferes with early events in viral transcription and inhibits ribonucleoprotein synthesis (Wray et al., 1985) . Although it was effective in experimentally infected animals, ribavirin has shown little effect on treating HRSV (Collins and Crowe, 2007; Empey et al., 2010; Welliver, 2010) . Palivizumab (Synagis) is effective at preventing HRSV infection (Collins and Crowe, 2007) . However, it is very expensive and is not effective at the therapy of an established infection (Collins and Crowe, 2007) . Therefore, effective chemotherapeutic agents are still urgently needed.
Sheng-Ma-Ge-Gen-Tang (SMGGT; Shoma-kakkon-to) has been used to manage pediatric viral infection. It has been proven to be effective at inhibiting HRSV-induced plaque formation in vitro (Wang et al., 2011) . Cimicifuga foetida L. is a major constituent of SMGGT. C. foetida has been used as a medical plant for anti-pyretic and detoxificative purposes in ancient China for thousands of years. C. foetida has anti-bacterial, antiinflammatory, and anti-neoplastic activities (Zhao and Xiao, 2006) . Several constituents of C. foetida have been proven to have anti-cancer (Sun et al., 2007; Tian et al., 2007) , collagenolytic (Kusano et al., 2001) , and anti-complement activities (Qiu et al., 2006) . However, its anti-viral activity has not been examined. We hypothesized that C. foetida, a major constituent of SMGGT, might have activities against HRSV. We used both human upper (HEp2) and low (A549) respiratory tract cell lines to prove that C. foetida was effective on cytopathic effects induced by HRSV.
Materials and Methods

Preparation of Hot Water Extracts of Cimicifuga foetida L.
Water extract of air-dried C. foetida L. Rhizoma was prepared as reported previously (Yen et al., 1991) . The authenticity of C. foetida was confirmed by Professor M.H. Yen at the Graduate Institute of Natural Products of Kaohsiung Medical University. Briefly, 100 g of C. foetida was shade-dried and decocted for 1 h with 1 L of boiling reverseosmotic water three times. The decoctions were mixed, filtered, concentrated and lyophilized. The w/w yield of C. foetida was 10.7%. The extract of C. foetida was then dissolved in minimum essential medium (MEM, Gibco BRL, Grand Island, NY, USA) and supplemented with 2 or 10% fetal calf serum (FCS) into the final concentrations ð10, 30, 100, 300 g/ml for bioactivity assay and up to 3000 g/ml for cytotoxicity test) before experiments.
Cells and Virus
Human larynx epidermoid carcinoma cells [HEp-2; ATCC (the American Type Culture Collection) CCL 23] and human lung carcinoma cells (A549 cells; ATCC CCL-185) were used to culture human respiratory syncytial virus (RSV Long strain: ATCC VR-26). Reagents and medium for cell culture were purchased from Gibco BRL. Cells were propagated at 37 C under 5% CO 2 in minimum essential medium (MEM) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin G sodium, 100 g/ml streptomycin sulfate and 0.25 g/ml amphotericin B. Virus was propagated on 90% confluent cell monolayer in MEM with 2% FCS and antibiotics as described above. Viral titer was determined by plaque assays and expressed as plaque forming units per ml (pfu/ml). Virus was stored at À70 C until use.
Cytotoxicity Assay
Cytotoxicity of C. foetida on proliferating cells was assayed by XTT-based method (Chiang et al., 2002) . Briefly, cells ð1 Â 10 4 cells/well) were seeded into 96-well culture plates (Falcon; BD Biosciences, USA) and incubated overnight at 37 C under 5% CO 2 . Then, the medium was removed and different concentrations ð30, 100, 300, 1000, 3000 g/ ml) of C. foetida were applied in triplicate. After three days of incubation, the cytotoxicity of C. foetida was determined by XTT (sodium 3 0 -[1-(phenylamino-carbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid) kits (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions. The 50% cytotoxic concentration (CC 50 Þ of C. foetida was calculated by regression analysis of the doseresponse curve generated from the data.
Antiviral Effectiveness Assay by Plaque Reduction Assay
Antiviral activity of C. foetida was examined by a plaque reduction assay modified from procedures previously described (Graham et al., 1988; Chen et al., 2010) . Briefly, cells ð1 Â 10 5 /well) were plated in 12-well culture plates for 24 h and were inoculated with a mixture of 200 pfu/well HRSV and various concentrations of C. foetida for 1 h. Ribavirin (Sigma, St. Louis, USA) was used as a positive control. After supplement of overlay medium (MEM plus 2% FCS in 1% methylcellulose), they were cultured at 37 C under 5% CO 2 for three days. The monolayers were fixed with 10% formalin, stained with 1% crystal violet, and the plaques were counted. The minimal concentration required to inhibit 50% cytopathic effect (IC 50 Þ of C. foetida was calculated by regression analysis of the dose-response curve generated from the data.
Time Course Assay
Antiviral activity of C. foetida was examined before and after viral inoculation by plaque reduction assay modified from procedures mentioned above (Graham et al., 1988; Chang et al., 2008; Chen et al., 2010) . Briefly, cells were seeded and incubated for 24 h as previously described. C. foetida of various concentrations was supplemented at À2 h (2 h before viral inoculation), À1 h (1 h before viral inoculation), or 1 h or 2 h (1 h or 2 h after viral inoculation). Supernatant was removed before supplement of overlay medium. They were incubated for a further 72 h as mentioned above. After fixation, crystal violet was supplemented and the plaques were counted.
Attachment Assay
The effect of C. foetida on viral attachment was evaluated by a plaque reduction assay modified from procedures previously described (De Logu et al., 2000; McLellan et al., 2010) . Heparin (Sigma, St. Louis, USA) was used as a positive control. Briefly, cells were seeded and incubated for 48 h. The cells were pre-chilled at 4 C for 1 h and the medium was removed. The cells were infected with a mixture of 200 pfu/well HRSV and various concentrations of C. foetida. After incubation at 4 C for another 3 h, the free virus was removed. The cell monolayer was washed with ice-cold phosphate-buffered saline (PBS) thrice, covered with overlay medium, incubated for further 72 h at 37 C under 5% CO 2 , and examined by plaque assay as described earlier.
Internalization Assay
The effect of C. foetida on viral internalization was also evaluated by a plaque reduction assay described earlier (De Logu et al., 2000) . Briefly, the cell monolayer was grown in 12-well culture plates and pre-chilled at 4 C for 1 h. Cells were infected with 200 pfu/well HRSV and incubated at 4 C for 3 h to allow virus binding without internalization. The virus-containing medium was replaced with fresh medium containing various concentrations of C. foetida and cultured at 37 C. In 20 min intervals, acidic PBS (pH 3) was supplemented for one minute to deactivate un-internalized virus followed by alkaline PBS (pH 11) for neutralization. Then, PBS was replaced by fresh overlay medium. After incubation at 37 C for further 72 h, the cell monolayer was examined by the plaque assay.
Interferon-ß (IFN-ß) and Tumor Necrosis Factor-(TNF-) Assay
After the experiment of antiviral effectiveness assay mentioned above, the culture medium was collected and assayed by the IFN-β ELISA kit (PBL Biomedical Laboratories, Piscataway, USA) and TNF-ELISA kit (R&D Systems, Minneapolis, USA) according to the manufacturer's instruction. The A 450 nm was determined with ELISA reader (Multiskan EX, Labsystems). 
Statistical Analysis
Results were expressed as mean AE standard deviation (S.D.). Percentage of the control (infection rate; %) was calculated from the plaque counts of C. foetida groups divided by that of viral control group. Data were analyzed with ANOVA by JMP 7.0.1 software (SAS Institute, Cary, NC, USA). Tukey honestly significant difference (HSD) test was used to compare all pairs of groups in the ANOVA test. p < 0:05 was considered statistically significant.
Results
Cytotoxicity Assay
C. foetida did not show any cytotoxicity against both HEp-2 and A549 cells at concentrations up to 3000 g/ml (Fig. 1) . Instead, C. foetida might slightly increase the proliferation of HEp-2 cells. The estimated CC 50 was more than 3000 g/ml. The higher CC 50 proved its safety.
Antiviral Effectiveness Assay
C. foetida and ribavirin were dose-dependently ( Fig. 2 ; p < 0:0001) effective against HRSV in both HEp2 cells and A549 cells. C. foetida was more effective in A549 cells ( Fig. 2A ; p < 0:0001). However, the effect of ribavirin was similar in both HEp-2 cells and A549 cells (Fig. 2B) . The IC 50 of C. foetida was 67.3 g/ml in HEp-2 cells and 31.0 g/ml in A549 cells. C. foetida was effective ðp < 0:0001Þ both before and after viral inoculation in both HEp-2 cells and A549 cells in a dose-dependent manner. C. foetida had a better effect when given after viral inoculation in HEp-2 cells (Fig. 3A) . In HEp-2 cells, the IC 50 was 261.0 g/ml (2 h before viral inoculation), 232.8 g/ml (1 h after viral inoculation), and 151.3 g/ml (2 h after viral inoculation). Its effect on A549 cells was similar (Fig. 3B) ; however, with no time-dependent effect. When it was supplemented 2 h after viral inoculation,C. foetida could show a better anti-HRSV activity at concentrations higher than 100 g/ml in A549 cells. Its IC 50 was 205.4 g/ml (2 h before viral inoculation), 268.5 g/ml (1 h before viral inoculation), 212.4 g/ml (1 h after viral inoculation), and 150.0 g/ml (2 h after viral inoculation) in A549 cells.
Attachment Assay
Since C. foetida could effectively inhibit HRSV-induced plaque formation when given before HRSV infection, C. foetida was hypothesized to be effective on viral attachment and/or internalization. The results of attachment assay confirmed this assumption. C. foetida dose-dependently inhibited viral attachment in both HEp-2 cells and A549 cells ( Fig. 4A ; p < 0:0001), with a better effect on A549 cells ðp < 0:0001Þ. The IC 50 was 82.1 g/ml in HEp-2 cells and 70.6 g/ml in A549 cells. Heparin could dose-dependently prevent RSV attachment ( Figure 2. C. foetida were effective against HRSV in antiviral effectiveness assay. Both C. foetida (A) and ribavirin (B) were dose-dependently ðp < 0:0001Þ effective against HRSV determined by the plaque reduction assay. C. foetida was more effective in A549 cells ðp < 0:0001Þ. However, ribavirin did not show the difference. Data were presented as mean AE S.D. of nine tests. * p < 0:05; ** p < 0:001; *** p < 0:0001 compared to the viral control. 0.01 g/ml heparin were 19.5 g/ml and 13.1 g/ml in HEp-2 and A549 cells, respectively. It is interesting to note that C. foetida initially had a higher IC 50 on viral attachment in HEp-2 cells. However, when it was combined with heparin, C. foetida had a lower IC 50 in A549 cells. Moreover, 0.001 g/ml heparin unexpectedly showed a synergistic effect with C. foetida (µg/ml) Infection rate (% of control) 0.01 µg/ml heparin; A549 cell 0.001 µg/ml heparin; A549 cell 0.01 µg/ml heparin; HEp-2 cell 0.001 µg/ml heparin; HEp-2 cell ** * ** ** ** ** ** *** *** *** *** *** *** *** *** (B) C. foetida and heparin effect 30 g/ml C. foetida. The effects of different concentrations of heparin with 30 g/ml C. foetida were similar (Fig. 4B) .
Internalization Assay
C. foetida was time-dependently and dose-dependently ( Fig. 5 ; p < 0:0001) effective on HRSV internalization in both HEp-2 and A549 cells. The effects were quite similar in both cells. C. foetida had a IC 50 of 118.7 g/ml (20 min incubation), 37.4 g/ml (40 min), 25 g/ml (60 min) in A549 cells, and 180.9 g/ml (20 min incubation), 94.9 g/ml (40 min), 29.6 g/ml (60 min) in HEp-2 cells.
Interferon-ß (IFN-ß) and Tumor Necrosis Factor-(TNF-) Assay
The basal IFN-β and TNF-secretion in both A549 and HEp-2 cells was similar (Fig. 6) . After HRSV infection, IFN-β and TNF-secretion could be stimulated ( Fig. 6 ; p < 0:05). C. foetida could stimulate IFN-β secretion in both HEp-2 and A549 cells with or without HRSV infection (Figs. 6A and 6B; p < 0:0001). This effect was more prominent on A549 cells ðp < 0:0001Þ. In contrast, C. foetida did not stimulate TNF-secretion in both HEp-2 and A549 cells with or without HRSV infection (Figs. 6C and 6D ).
Discussion
HRSV can infect upper respiratory mucosa and replicate initially in the nasopharynx (Collins and Crowe, 2007) . HRSV can spread rapidly to the lower respiratory tract possibly by aspiration of secretions (Collins and Crowe, 2007) . HRSV primarily causes morbidity and mortality by the pathology of the lower respiratory tract (Collins and Crowe, 2007) . Therefore, management of HRSV infection needs an effective strategy to inhibit viral infection of both upper and lower respiratory tracts. This experiment showed that C. foetida was effective at inhibiting RSV-induced plaque formation in both human upper (HEp-2) and lower (A549) respiratory tract cells. Therefore, C. foetida could inhibit viral replication in the nasopharynx. Furthermore, 300 g/ml C. foetida could inhibit HRSV-induced plaque formation to less than 10% of the control in lower respiratory tract (A549) cells. Therefore, higher concentrations of C. foetida could largely inhibit HRSV-induced morbidity and mortality. When given after viral inoculation, C. foetida had a similar effect to that of giving after HRSV inoculation in the time course assay. Its preventive activity was further supported by an attachment assay and an internalization assay. Therefore, C. foetida was effective at preventing and managing HRSV infection. Heparin is highly effective at preventing HRSV attachment (McLellan et al., 2010) . C. foetida could further increase the effect of heparin. Furthermore, C. foetida had a synergistic effect with 0.001 g/ml heparin. Therefore, C. foetida could have mechanisms difference from those of heparin. Other than preventing viral attachment and internalization, C. foetida could stimulate IFN-β to prevent HRSV infection. HRSV infection will induce cellular production of IFN-β and TNF-(McCann and Imani, 2007) . Both IFN and TNF contribute to innate immunity against viral infection (Bartee et al., 2008; Benedict et al., 2003; McFadden et al., 2009) . C. foetida could stimulate both HEp-2 and A549 cells to secrete IFN-β with or without HRSV infection. Therefore, along with direct cytoprotection, C. foetida could be useful for preventing and managing viral infection by stimulating IFN-β. Although it is a potent antiviral cytokine, TNF-can activate p38MAPK to induce apoptosis of bronchial epithelia (Gallelli et al., 2010) . C. foetida could not induce TNF-secretion in both HEp-2 and A549 cells. Therefore, C. foetida could be active against HRSV infection without inducing apoptosis of respiratory mucosa. Most of the therapeutic reagents under development aimed at inhibiting viral entrance (Empey et al., 2010; Welliver, 2010) . However, C. foetida was also effective after viral inoculation, especially on HEp-2 cells, a human larynx epidermoid carcinoma cells. HRSV replicates initially in the upper respiratory mucosa (Collins and Crowe, 2007) . Therefore, C. foetida could be a better candidate to manage RSV infection. In this study, C. foetida had low IC 50 s in antiviral effectiveness assay in which both HRSV and C. foetida were concomitantly supplemented. Therefore, the IC 50 s should show a logical trend between antiviral effectiveness assay and time course assay. However, the IC 50 was 31.0 g/ml in A549 cells when C. foetida was concomitantly supplemented with HRSV. When C. foetida was supplemented 2 h before viral inoculation in A549 cells, the IC 50 s were 205.4 g/ml. The IC 50 did not change much from 268.5 g/ml (1 h before viral inoculation), 212.4 g/ml (1 h after viral inoculation), to 150.0 g/ml (2 h after viral inoculation). The IC 50 in antiviral effectiveness assay was much lower than that of time course assay. It lacked a logical trend between the time course assay and the antiviral effectiveness assay. This might raise a question about the validity of the experiment. However, our results clearly showed C. foetida was also effective when supplemented after viral inoculation. During the time course assay, C. foetida was removed before the supplement of overlay medium. Nevertheless, C. foetida remained there in the antiviral effectiveness assay to exert its antiviral effect. Therefore, the results of the antiviral effectiveness assay were the summation of all effects in the time course assay, so it was reasonable to have a lower IC 50 in the antiviral effectiveness assay.
C. foetida could prevent RSV infection by inhibiting viral attachment, internalization, and by stimulating IFN-β secretion. Furthermore, C. foetida could be effective at inhibiting plaque formation after HRSV inoculation. C. foetida was quite different from therapeutic
